{"disease":{"id":"first-line-treatment-of-metastatic-nsclc-with-specific-egfr-mutations","name":"first line treatment of metastatic nsclc with specific egfr mutations"},"drugs":{"marketed":[{"drug_id":"chembl-chembl939","indication_name":"First-line treatment of metastatic NSCLC with specific EGFR mutations","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"GEFITINIB","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"Kinase Inhibitor [EPC]","quality_score":20,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":1,"totalPipeline":0},"trials":{"data":[],"total":0},"guidelines":[],"source":"Drug Landscape verified database"}